Mendus Investor Relations Material
Latest events
Q1 2025
Mendus
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mendus
Access all reports
Mendus AB, a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. The company's main focus is on the development of prophylactic and therapeutic dendritic cell vaccines based on ilixadencel for the treatment of different solid tumor types. It is also involved in the development of INTUVAX, an allogeneic tumor cell vaccine to be used following surgery and anti-cancer therapy in patients with colorectal cancer or hepatocellular carcinoma to prevent recurrences.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
IMMU
Country
🇸🇪 Sweden